24小时热门版块排行榜

>论坛更新日志 (3807)
>导师招生 (699)
>论文投稿 (390)
>休闲灌水 (217)
>硕博家园 (211)
>文献求助 (137)
>考博 (135)
>新药研发 (98)
>公派出国 (78)
>学术会议 (73)
>考研 (67)
>虫友互识 (65)
>基金申请 (56)
>论文道贺祈福 (48)
>教师之家 (44)
>招聘信息布告栏 (39)

返回列表

letterman

新虫 (小有名气)

应助: 0 (幼儿园)
金币: 288.3
帖子: 60
在线: 3小时
虫号: 23499739
注册: 2020-09-08
性别: GG
专业: 药物设计与药物信息

[交流] Postdoc position in Med Chem, McGill University, Canada

Position:  Postdoctoral fellow in Medicinal Chemistry, under the supervision of Dr. Jian Hui Wu, Lady Davis Institute, McGill University, Montreal, Canada.

Project description:
Our laboratory is interested in identification and optimization of novel inhibitors against cancer targets. As a key member of our team, the candidate is expected to chemically optimize the initial active compounds. We routinely utilize structure-based approaches to identify top-ranking analogues to be synthesized. Our laboratory includes three components: structure-based drug design, Medicinal chemistry and biological evaluations.
The funded projects are as follows:

1) Postdoc position 1:  The start time is OCT, 2020. This funded project is to develop novel inhibitors of RanGTPase for ovarian cancer.  Our preliminary work has discovered initial hits as novel inhibitors of RanGTPase, which are selectively active against the ovarian cancer cells, with no obvious effects on normal cells.

2) Postdoc position 2:  The start time is NOV, 2020. This funded project is to develop novel modulators of Keap1/Nrf2 protein-protein interaction for lung cancer. Keap1 is an endogenous inhibitor of Nrf2. In normal cells, complexation of Keap1 with Nrf2 lead to Nrf2 degradation, resulting in basal level of Nrf2. However, mutation in Keap1 leads to Keap1 mutant that is unable to form a complex with Nrf2, resulting in high level of Nrf2 in cancer cells, which confer drug resistance in cancer patients. Our project is to discover compounds that could repair the interaction of Keap1 mutant with Nrf2, with a view to selectively suppressing Nrf2 level in cancer cells, which subsequently sensitize cancer cells to cancer treatment. We have already discovered initial hits that are selectively active against the Keap1 mutants, which are found in cancer cells, but have no effect on the wild-type Keap1, that are found in normal cells.

Qualifications:
We are looking for someone who is interested in anticancer drug discovery. The candidate should have a Ph.D. degree in Organic Chemistry/Medicinal Chemistry, which was obtained in 2018 or later.

Language required: English

Contact:
Interested individuals should send a cover letter, CV and the coordinates of 2-3 referees to Dr. Jian Hui Wu  (email address:  Jian.H.Wu@McGill.CA).

回复此楼